HeartSciences pivots from AI cardiology to Zcash mining via merger

A Nasdaq-listed AI medtech company is abandoning its healthcare identity to become a DCG-backed privacy-coin mining platform.

By Disrupts Editorial Team Tue, 10 November 2026 AI level 2 of 5

AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean

A well-lit data center aisle with multiple glowing blue cables looping across the floor and connecting to rows of server racks, with a bright window visible in the distance.

HeartSciences Inc., a Texas-based AI-powered electrocardiography company listed on Nasdaq under HSCS, has filed its definitive proxy statement with the SEC for a proposed all-stock merger with Fortitude Mining Holdings, a vertically-integrated digital asset mining platform owned by Digital Currency Group (DCG). If shareholders approve the deal at a special meeting scheduled for 19 November 2026, the combined entity will rebrand as Fortitude and trade under the ticker "TUDE," effectively retiring HeartSciences as a going concern in its current form.

The transaction is one of the more striking pivot stories to emerge from the small-cap Nasdaq universe in recent memory. HeartSciences' MyoVista platform had positioned the company at the intersection of AI and clinical cardiology, a space attracting genuine institutional interest as diagnostic AI seeks FDA pathways. Fortitude, by contrast, is anchored in Zcash (ZEC), a privacy-preserving proof-of-work cryptocurrency that sits well outside mainstream institutional digital asset allocations, which have converged around Bitcoin and, to a lesser degree, Ethereum.

A Shell-Flip or a Strategic Bet?

The mechanics of the transaction look structurally similar to a reverse merger: a listed but relatively small medtech company absorbs a private operating entity owned by a larger parent, providing DCG's Fortitude subsidiary with a ready-made public market listing without the cost and scrutiny of a traditional IPO. DCG, one of the most prominent, and, since the collapse of Genesis Capital in 2023, one of the most embattled, conglomerates in the digital asset industry, retains the role of parent to Fortitude going into the transaction. The proxy statement notes that certain DCG executive officers may be deemed participants in the shareholder solicitation, underscoring the degree to which the legacy owner's interests are woven into the proposed deal.

Fortitude's operational model pairs self-mining operations with owned data centre infrastructure and a diversified power portfolio backed by long-term contracts. The company says it currently monetises all digital assets mined, including ZEC, rather than holding them on its balance sheet, a posture that limits cryptocurrency price exposure but also limits the upside that has driven speculative interest in Bitcoin treasury strategies at companies such as MicroStrategy (now Strategy).

Cross-Sector Capital Implications

The deal sits at the collision point of two sectors facing very different macro conditions. AI-enabled medtech is attracting patient capital from life-sciences investors and strategic acquirers willing to underwrite the long regulatory cycle from CE mark or FDA clearance through to reimbursement. Digital asset mining, meanwhile, is structurally sensitive to proof-of-work energy costs, network hash-rate competition, and the notoriously unpredictable price of the underlying coin, risks the proxy statement acknowledges explicitly, flagging "substantial volatility of Zcash and other digital asset prices" among the material closing-condition risks.

For cross-sector investors, the transaction raises a pointed capital-allocation question: at a moment when AI-medtech is positioned as one of the cleaner convergence trades, combining FDA-addressable markets with compounding model improvements, does abandoning that position for a Zcash mining play represent a rational redeployment of a listed vehicle, or a distress-signal pivot by a company that lacked the balance sheet to compete in its original market? The HeartSciences board's unanimous recommendation to vote in favour suggests the former, but the market's verdict will be visible in HSCS price action between now and the 19 November shareholder vote.

More broadly, the transaction is a reminder that the small-cap Nasdaq tier continues to function as a liquidity bridge for private digital-asset operators seeking public-market exposure outside the traditional IPO window. Whether that bridge is widening, as spot Bitcoin ETF approval normalises institutional digital-asset access, or narrowing as regulatory scrutiny of proof-of-work mining intensifies in the US, will determine how many more HeartSciences-style pivots the market absorbs in the quarters ahead.